27
March 2024
hVIVO plc
("hVIVO", the "Company" or
the "Group")
Notice of
results
hVIVO plc (AIM & Euronext:
HVO), a rapidly growing specialist contract research
organisation (CRO) and world leader in testing infectious and
respiratory disease products using human challenge clinical trials,
announces that it will release its full year
results for the twelve months ended 31 December 2023 on Tuesday 9
April 2024.
Analyst briefing
A briefing open to equity research analysts
will take place on Tuesday 9 April 2024 at 12.00 pm BST. To
register and for more details please contact Walbrook PR on
hvivo@walbrookpr.com.
Investor presentation
Yamin 'Mo' Khan, Chief Executive
Officer, and Stephen Pinkerton, Chief Financial Officer, will
provide a live presentation relating to the full year results via
the Investor Meet Company platform on Tuesday 9 April 2024 at 6.00
pm BST.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9am the
day before the meeting or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet hVIVO
here. Investors who already
follow hVIVO on the Investor Meet Company platform will
automatically be invited.
For
further information please contact:
|
hVIVO plc
|
+44 (0) 20
7756 1300
|
|
Yamin 'Mo' Khan, Chief Executive Officer
Stephen Pinkerton, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint
Broker)
|
+44 (0) 20
7220 0500
|
|
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward
|
|
|
|
|
|
Peel Hunt LLP (Joint
Broker)
|
+44 (0)20
7418 8900
|
|
James Steel, Dr Christopher Golden
|
|
|
|
|
|
Davy (Euronext Growth Adviser and Joint
Broker)
|
+353 (0) 1
679 6363
|
|
Anthony Farrell, Niall
Gilchrist
|
|
|
|
|
|
Walbrook PR (Financial PR & IR)
Stephanie Cuthbert / Phillip
Marriage /
Louis Ashe-Jepson
|
+44 (0) 20
7933 8780 or hvivo@walbrookpr.com
+44 (0)
7796 794 663 / +44 (0) 7867 984 082 /
+44 (0) 7747 515 393
|
|
|
|
|
| |
Notes to
Editors
About
hVIVO
hVIVO
plc (ticker: HVO) (formerly Open Orphan plc)
is a rapidly growing specialist contract research organisation
(CRO) and the world leader in testing infectious and respiratory
disease vaccines and therapeutics using human challenge clinical
trials. The Group provides end-to-end early clinical development
services to its large, established and growing repeat client base,
which includes four of the top 10 largest global biopharma
companies.
The Group's fast-growing services business
includes a unique portfolio of 11 human challenge models, with a
number of new models under development, to test a broad range of
infectious and respiratory disease products. The Group has world
class challenge agent manufacturing capabilities, specialist drug
development and clinical consultancy services via its Venn Life
Sciences brand, and a lab offering via its hLAB brand, which
includes virology, immunology biomarker and molecular testing. The
Group offers additional clinical field trial services such as
patient recruitment and clinical trial site services.
hVIVO runs challenge studies
in London from its Whitechapel quarantine clinic, its
state-of-the-art QMB clinic with its highly specialised on-site
virology and immunology laboratory, and its clinic in Plumbers
Row. To recruit volunteers / patients for its studies, the Group
leverages its unique clinical trial recruitment capability via
its FluCamp volunteer
screening facilities in London and Manchester.